A water-extractable active substance for inhibiting infection of COVID-19 XBB 1.5 variant strain and its application
The problem of infection of the COVID-19 XBB 1.5 variant strain was solved by extracting active substances in the water of rock cabbage, and effective inhibition of the variant strain was achieved, providing a new treatment and prevention means.
Patent Information
- Application Number
- CN202310914606.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-07-25
AI Technical Summary
The COVID-19 XBB 1.5 variant poses a special risk to vulnerable populations, and prior art is difficult to effectively inhibit their infection, especially by interfering with the interaction of the virus with the ACE2 receptor.
The active substance was extracted by rock cabbage water, and the water extract obtained by drying, extraction and drying treatment was used to interfere with ACE2-RBD protein interaction and inhibit SARS-CoV-2 virus infection.
岩白菜水浸提活性物显示出显著的抗感染能力,能够有效抑制COVID-19 XBB 1.5变异株的感染,提供了一种潜在的治疗和预防手段。
Smart Images

Figure CN116785332B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medicine, and in particular to a water-extractable active substance for inhibiting infection of a COVID-19 XBB 1.5 variant strain and an application thereof. Background Art
[0002] The COVID-19 virus poses a particular risk to vulnerable populations, especially the elderly or those with underlying health problems. The spike (S) protein of the COVID-19 virus plays a crucial role in penetrating and infecting human cells. The S protein facilitates the entry of the virus into these cells by interacting with the angiotensin-converting enzyme 2 (ACE2) receptor present on the surface of human cells. The S protein is a glycoprotein composed of two subunits, S1 and S2, and plays a crucial role in the entry and replication of the virus. In the S1 subunit, there is a receptor binding domain (RBD) that is responsible for recognizing and binding to the ACE2 receptor. On the other hand, the S2 subunit promotes the fusion of the viral membrane with the host cell membrane, allowing the virus to invade and replicate inside the host cell. The ACE2 receptor is widely distributed in various tissues of the human body, especially in the lungs, heart and kidneys. The interaction of the virus's S protein with the ACE2 receptor causes structural changes that facilitate viral entry and infection; after the virus enters the cell, its genetic material (RNA) is released into the cytoplasm, and the virus then controls the cell's machinery to begin replicating, producing more viral particles; these particles are subsequently released from the infected cells, allowing the virus to spread throughout the body, a process that can damage infected cells and cause tissue damage and inflammation, especially in the lungs; as the virus progresses, it can cause widespread inflammation, leading to severe symptoms such as fever, cough and difficulty breathing; researchers are currently exploring potential treatments targeting the S protein to interfere with its interaction with the ACE2 receptor, thereby blocking viral entry and infection; further research is essential to fully understand this interaction and develop effective treatments and vaccines for COVID-19. Summary of the invention
[0003] In view of the deficiencies in the prior art, the present invention provides a water-extractable active substance for inhibiting infection by the COVID-19 XBB 1.5 variant and its application to solve the above-mentioned problems.
[0004] The present invention provides a water-extract active substance for inhibiting infection of a COVID-19 XBB 1.5 variant strain and an application thereof. The water-extract active substance for inhibiting infection of a COVID-19 XBB 1.5 variant strain is a water-extract active substance of Bergenia oleracea.
[0005] The water extraction method of the Bergenia water extract active ingredient is:
[0006] Step 1: The whole Bergenia herb was air-dried in a drying room at room temperature for five days;
[0007] Step 2: Cut the bergamot into 0.5 cm long segments and put them into a nylon mesh bag;
[0008] Step 3: Weigh and add 30 times the weight of the herbs into the extractor. Once the water boils, extract the herbs for 2 hours.
[0009] Step 4: Drying the water extract in an electric drying oven at a temperature of 60° C. to obtain a dry water extract powder;
[0010] Step 5: Re-dissolve the dried water extract powder in pure water, remove insoluble matter by filtration, and dry it again in a drying oven at 60° C. to obtain the water-extracted Bergenia active ingredient.
[0011] The active substance of the Bergenia oleifera water extract is used as an inhibitor of COVID-19 XBB 1.5 variant infection in medicine.
[0012] Application of the Bergenia oleracea water extract active ingredient in preventing and treating COVID-19 XBB 1.5 variant infection.
[0013] The beneficial effects of the present invention are: the active ingredients of the water extract of Bergenia can be used to prevent and treat COVID-19 XBB 1.5 variant infection; and the active ingredients of the water extract of Bergenia can be used in medicine as inhibitors of COVID-19 XBB 1.5 variant infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 It is a standard curve diagram in an embodiment of the present invention;
[0015] Figure 2 It is a histogram of the initial screening concentration in an embodiment of the present invention;
[0016] Figure 3 This is a toxicity test diagram of 11# Bergenia in an embodiment of the present invention;
[0017] Figure 4 This is a toxicity test diagram of 43# sour vine fruit in an embodiment of the present invention;
[0018] Figure 5 This is a graph showing the inhibition rate of 11# Bergenia in an embodiment of the present invention;
[0019] Figure 6 This is a graph showing the inhibition rate of 43# sour vine fruit in an embodiment of the present invention;
[0020] Figure 7 is a cell image in an embodiment of the present invention;
[0021] Figure 8 This is a scatter plot of the activity of 11# Bergenia and 43# Sourvine Fruit in the examples of the present invention. DETAILED DESCRIPTION
[0022] Example 1
[0023] The present invention provides a water-extracted active substance for inhibiting infection of COVID-19 XBB 1.5 variant strain and an application thereof, wherein the water-extracted active substance for inhibiting infection of COVID-19 XBB 1.5 variant strain is a water-extracted active substance of tartaria;
[0024] To find effective active substances that can interfere with ACE2-RBD protein interaction (PPI) and inhibit SARS-CoV-2 virus infection, 64 commonly used Chinese herbal medicines were screened using the COVID-19 serum neutralizing antibody fluorescence immunochromatography kit and a preliminary activity evaluation was performed; subsequently, an in vitro infection model was established using the COVID-19 XBB1.5 variant and Vero E6 cells; this model was then used to verify the anti-infection ability of the active water extract;
[0025] Materials and Experimental Methods
[0026] Experimental Materials
[0027] The herbs used were obtained from local Chinese medicine markets, and special precautions were taken to ensure their cleanliness. The plant surfaces were thoroughly washed using purified water to remove any dirt or soil residues. Subsequently, the water on the plant surface was evaporated under controlled room temperature conditions. This was followed by an identification process by plant taxonomy experts. Any herbs that could not be identified were excluded, and ultimately 64 herbs were selected for the subsequent research phase.
[0028] SARS-CoV-2S1 protein (40591-V08H), human ACE2 protein (10108-H08H), COVID-19 neutralizing antibody (40591-MM43), and COVID-19 nucleoprotein antibody (40143-R004) were purchased from Beijing Sifangda Biotechnology Co., Ltd. (Beijing, China);
[0029] XBB1.5 mutants and Vero-E6 cells were provided by Guangzhou Customs Technology Center (Guangzhou, Guangdong, China);
[0030] Immunochromatographic test strips were manufactured and provided by Qinghai Artimite Biotechnology Co., Ltd. (Xining, Qinghai, China);
[0031] The dry fluorescent immunoassay analyzer was provided by Qinghai Artimite Biotechnology Co., Ltd. (Xining, Qinghai, China);
[0032] Method for preparing herbal extracts
[0033] The herbs were air-dried in a drying room at room temperature for five days. Then, we used scissors to cut the herbs into 0.5 cm long segments and put them into nylon mesh bags. After weighing the herbs, we added purified water equivalent to 30 times the weight of the herbs to the extractor. Once the water boiled, we extracted the herbs for 2 hours. Subsequently, the water extract was dried at 60°C in an electric drying oven to obtain a dry water extract powder. Then, the dry powder was redissolved in purified water, filtered to remove insoluble matter, and dried again in a drying oven at 60°C. After complete drying, we stored the powder in sealed glass bottles and marked them with label paper. Finally, we stored them in a dry environment at room temperature.
[0034] Preliminary screening of herbal aqueous extracts
[0035] We used immunochromatography to evaluate the effectiveness of different herbal extracts in inhibiting the interaction between ACE2 and S1 proteins; the colloidal gold-labeled antibody kit for semi-quantitative detection of serum COVID-19 neutralizing antibodies developed by Tsinghua Aike Jiangyan Biotechnology Co., Ltd. has obtained the CE certification for medical devices in the Netherlands; based on their related technology, Tsinghua Aike Jiangyan Biotechnology Co., Ltd. provided us with a COVID-19 serum neutralizing antibody detection kit labeled with fluorescent microspheres, which is intended to preliminarily quantify our screening results;
[0036] We designed a T-line that exploits the interaction between ACE2 protein and S1 protein; this step involves labeling Eu fluorescent microbeads on S1 protein, which are then evenly distributed on a pre-treated glass fiber membrane and thoroughly dried; subsequently, ACE2 protein is fixed at the designated T-line position on the nitrocellulose membrane; in addition, we created a C-line by exploiting the interaction between natural chicken IgY antibody and goat anti-chicken IgY antibody; chicken IgY antibody is labeled with Eu fluorescent microbeads and evenly dispersed on a pre-treated glass fiber membrane; finally, goat anti-chicken IgY antibody is firmly fixed at the C-line position on the nitrocellulose membrane; individual test strips are carefully assembled into individual plastic housings; Qinghai Audime Biotechnology Co., Ltd. conducts meticulous quality checks on this production batch, and all sampled specimens meet their strict company standards;
[0037] like Figure 1As shown in the figure, in order to analyze the quantitative performance of the reagent paper strip and establish a standard curve graph, we performed the following steps: the purchased S1 neutralizing antibody was used as a reference and diluted in the sample treatment solution of the reagent paper strip to obtain various concentrations close to the IC50 value recommended in the antibody manual; after mixing, the antibodies of different concentrations were applied to the sample wells of the reagent paper strip; then, the test strip was placed horizontally and not moved for 15 minutes; the fluorescence values corresponding to the T line and C line were measured respectively using the fluorescent immunoassay analyzer of Qinghai Audime Biotechnology Co., Ltd.; regression analysis was performed using log2 (T line fluorescence value / C line fluorescence value) as the dependent variable and log2 (neutralizing antibody concentration) as the independent variable to obtain the standard curve; this A standard curve enabled us to determine the S1 neutralizing antibody concentration that was equivalent to the activity of the unknown sample; we refer to this activity assessment measure as the equivalent antibody concentration; based on the standard curve graph, we could proceed to measure the equivalent antibody concentration of different herbal extracts; we accurately weighed the water extracts of all herbs and dissolved them in the sample treatment solution that came with the reagent paper strip at a concentration of 3 mg / mL; we then applied the prepared samples to the sample wells of the immunochromatographic test strips and placed the test strips on a horizontal platform for 15 minutes; finally, we used a fluorescent immunoassay analyzer to perform the test and record the resulting equivalent antibody concentrations, as shown in Table 1, which allowed for a semi-quantitative assessment of the activity of all test samples;
[0038] Table 1 Screening the Biological Activity of 64Traditional TibetanMedicines
[0039]
[0040]
[0041]
[0042] The concentrations of 11# Bergenia and 43# Sourvine Fruit were significantly higher than those of other herbs;
[0043] HPLC detection of 11# Bergenia and 43# Sourvine Fruit
[0044] HPLC analysis was performed using a Hanbang high performance liquid chromatography system equipped with a dual wavelength UV detector; a Kromasil CN column (5 μm, 10.0 × 250 mm) was used for chromatographic separation; the mobile phase consisted of water-formic acid (A; 100:0.1, volume ratio) and acetonitrile-formic acid (B; 100:0.1, volume ratio), and a gradient elution program was used, with separation from 0% to 100% of B solution within 0 to 40 minutes; the flow rate was set at 4.0 mL / min; the compounds were detected at a wavelength of 210 nm in combination with a wavelength of 254 nm, and the column temperature was maintained at 55 °C;
[0045] Cell culture
[0046] The method for culturing Vero-E6 cells involves several steps; first, prepare complete culture medium, such as Dulbecco's modified MEM (DMEM) (Gibco, New York, USA), supplemented with 10% fetal bovine serum (FBS) (Gibco, New York, USA); next, thaw frozen Vero-E6 cells in a 37°C water bath until only a small ice crystal remains; transfer the cells to a sterile round-bottom tube and gently add pre-warmed complete culture medium; centrifuge the round-bottom tube at a low speed to pellet the cells and carefully remove the supernatant; suspend the cell pellet in complete culture medium and transfer to a T25 or T75 cell culture flask (BKMAN, Changsha, China); place the culture flask in an incubator at 37°C and 5% CO2; feed the cells regularly with fresh complete culture medium and monitor their growth and confluence; when the cells reach 80-90% confluence, wash with PBS and digest with trypsin-EDTA solution; add fresh complete culture medium to stop trypsin activity and transfer the cell suspension to a new bottle or culture dish;
[0047] Cytotoxicity test of 11# Bergenia and 43# Sourvine Fruit
[0048] like Figure 3-4As shown, the experimental setting includes three groups: sample treatment group, cell control group (normal cells), blank control group (no cells); the sample was diluted three-fold starting from 1000 μg / mL, with a total of 10 different concentrations; each concentration was tested in three replicate wells; Vero-E6 cells were cultured in a 96-well plate, and the supernatant was removed; then, 100 μL of the corresponding sample dilution was added to each well and incubated at 37°C and 5% CO2 for 24 hours; after the incubation, CCK-8 reagent was used for detection; the supernatant of the sample dilution was discarded, and 100 μL of DMEM medium without fetal bovine serum was added to each well, except for the wells of the blank control group; in addition, 10 μL of CCK-8 solution was added to each well, and the plate was incubated at 37°C and 5% CO2 for 2 hours; finally, the absorbance at 450 nm was measured using a spectrophotometer; a cell survival curve was generated to determine the maximum safe concentration of the sample;
[0049] Antiviral activity of samples tested using live viruses
[0050] The origin and quantification of the 2019-nCoV XBB1.5 variant, the complete genome sequence of which was previously determined by the Guangzhou Customs Technical Center; the complete genome sequence has been uploaded to the Nextclade database (https: / / clades.nextstrain.org / ) for comparison to determine the classification of the target virus; proving that the virus used in this study is indeed the COVID-19 XBB1.5.7 variant;
[0051] Vero E6 cells were cultured in a 96-well flat-bottom cell culture plate at a density of 2×104 cells per well; after 12 hours, when the cells reached 90% density, the supernatant was discarded; then, a 96-well round-bottom plate was prepared, and 180 μL of serum-free DMEM was added to each well; in row A, 20 μL of virus stock solution was added to each well, and then 10-fold dilutions were made, with 8 wells for each dilution; then, the diluted virus solution was added to the wells where the cell supernatant had been discarded, and 100 μL was added to each well; the plate was incubated at 37°C and 5% CO2 for 72 hours; the cytopathic effect (CPE) was observed and recorded, especially the number of wells showing CPE was recorded; subsequently, the TCID50 was calculated using the Reed-Muench method;
[0052] Activity verification experiment
[0053] like Figure 7As shown, in order to establish drug incubation medium, the active ingredients of 11# Bergenia and 43# Aconitifolia water extract were carefully diluted to reach the concentrations of 0.33, 0.11, 0.037, 0.012 and 0.0041 mg / ml, using D2 medium (DMEM+2% FBS); the experiment included three different groups: a control group with cells only, a virus infection group and a drug-virus interaction group; in each group, three parallel replicates of each drug dilution were used; before Vero E6 cells were infected with the virus, the cell culture supernatant was carefully replaced with the appropriate drug incubation medium, and 100 μL was added to each well; subsequently, the cells were incubated at 37°C in an environment containing 5% CO2 for 2 hours;
[0054] In a BSL-3 laboratory, after pre-treatment of the cell culture plate, the supernatant was discarded; Omicron XBB.1.5 virus was diluted in D2 medium (DMEM + 2% FBS) at an infection rate of 0.2; drug treatment medium was prepared by diluting the acid vine fruit water extract active substance in D2 medium (DMEM + 2% FBS) to concentrations of 0.66, 0.22, 0.073, 0.024 and 0.0081 mg / ml; these five drug concentrations were used as treatment points; then, the diluted virus was mixed with the corresponding concentration of drug in equal volumes; the mixture was added to the cell culture plate at a volume of 50 μL per well; the cells were incubated at 37°C and 5% CO2 for 1 hour; after incubating the virus-containing medium for 1 hour, the supernatant was discarded; subsequently, 100 μL of D2 medium (DMEM + 2% FBS) containing the appropriate drug concentration was added to each well; next, the culture plate was incubated at 37°C and 5% Incubate for 24 h at a CO2 concentration;
[0055] In the BSL-3 laboratory, 200 μL of 4% PFA fixative was added to each well to inactivate the virus and fix the cells; after fixation at room temperature for more than 1 hour, the fixative was aspirated and another 200 μL of 4% PFA fixative was added; the external surface of the cell culture plate was disinfected in preparation for subsequent analysis; the fixed cells in the wells were thoroughly washed with PBS buffer and then treated with Triton-X100; next, the cells were incubated with a rabbit monoclonal antibody against the SARS-CoV-2 core protein for 1 hour at room temperature; after a thorough washing step to remove any excess primary antibody, the cells were incubated with AlexaFluor 488-labeled anti-rabbit IgG for another 1 hour; finally, DAPI was used to stain the cell nucleus as a control for cell counting; the Celigo system was used to quantitatively evaluate the fluorescence intensity in the cell culture plate and capture cell images, such as Figure 7 As described above, to determine the level of viral infection;
[0056] Experimental Results
[0057] Establishment of screening method
[0058] like Figure 1 As shown, Eu fluorescent microspheres were selected to label S1 protein and chicken IgY antibody, respectively, and chromatography experiments were performed; when interacting with the T line coated with ACE2, the Eu fluorescent microspheres labeled with S protein formed a bright fluorescent line at the position of the T line; similarly, when interacting with the C line coated with sheep anti-chicken IgY antibody, the Eu fluorescent microspheres labeled with chicken IgY produced a striking fluorescent line; in the presence of an inhibitor, the binding between the S protein and ACE2 was hindered, resulting in a decrease in the fluorescence of the T line; however, regardless of the sample liquid, the fluorescence on the C line remained unchanged and was not affected;
[0059] In order to perform semi-quantitative analysis, it is essential to establish a standard curve for the fluorescent test strip; for this purpose, purified recombinant SARS-CoV-2 S1 protein neutralizing antibodies were used; the antibodies were diluted with the sample solution of the reagent strip to obtain six different concentrations ranging from 1 to 60 μg / mL; each diluted antibody solution was then applied to the sample well of the reagent strip; after 15 minutes of incubation, the fluorescence values were recorded; the collected data showed a linear relationship, such as Figure 1 As shown; the standard curve equation shows a high correlation coefficient, expressed as an R2 value of 0.97, indicating good correlation; this standard curve equation can be used for subsequent semi-quantitative analysis;
[0060] Screening of active aqueous extracts
[0061] In the preliminary screening experiment, all water extract active samples were used at the same concentration of 3 mg / mL, and each sample was repeated twice; Table 1 and Figure 2 It was shown that the active ingredients of 11# Bergenia and 43# Acanthocarpus sylvestris water extracts showed an abnormal activity better than 1000μg / mL neutralizing antibodies; then, Figure 8 As shown, the inhibitory activities of the aqueous extracts of 11# Bergenia and 43# Aconitifolia were tested repeatedly, starting from an initial concentration of 3 mg / mL and reaching final concentrations of 0.25, 0.13, 0.063, 0.031, 0.016, 0.0078, and 0.0039 mg / mL to verify the preliminary screening results; Figure 5-6 As shown, for a concentration of 3 mg / mL, the antibody concentration of the active substance of the water extract of sour vine fruit was greater than 1000 μg / mL; as the concentration decreased, the inhibitory activity weakened; the active substance of the water extract of sour vine fruit showed a concentration-activity effect in its inhibitory characteristics, and its inhibitory effect had good repeatability.
Claims
1. Use of a water-extracted active substance in the preparation of a drug for inhibiting infection by the COVID-19 XBB 1.5 variant, characterized in that: The water-extractable active substance is a water-extractable active substance of Bergenia oleracea, and the water extraction method of the water-extractable active substance of Bergenia oleracea is: Step 1: The whole Bergenia herb was air-dried in a drying room at room temperature for five days; Step 2: Cut the bergamot into 0.5 cm long segments and put them into a nylon mesh bag; Step 3: Weigh and add 30 times the weight of the herbs into the extractor. Once the water boils, extract the herbs for 2 hours. Step 4: Drying the water extract in an electric drying oven at a temperature of 60° C. to obtain a dry water extract powder; Step 5: Re-dissolve the dried water extract powder in pure water, remove insoluble matter by filtration, and dry it again in a drying oven at 60° C. to obtain the water-extracted Bergenia active ingredient.
